Actin advances Actimab-A studies in combination with PD-1 inhibitors for solid tumors

Washington (DPA-AFX) -Actinium Pharmaceuticals, Inc. (ATNM) launched a clinical program on Tuesday that evaluates the ACTIMAB-A in combination with PD-1 pebromumab-keytruda and nivolumab opdivo inhibitors.

These immunotherapies generated $ 38.8 billion in 2024 in different tumor indications, but limitations of the effectiveness of the face -due -derived -derived suppressors, which help tumors to detect immunity detection. Actimab a target CD33, an antigen expressed by MDSCs, which aims to increase the effectiveness of PD-1 inhibitors by exhausting these immune cells.

The program includes controlled clinical trials, from the head, which compare ACTIMAB with PD-1 inhibitors compared to PD-1 inhibitors alone in patients with squamous and throat-hnscc cell carcinoma and small cell lung cancer.

Studies will evaluate safety, general response rate – Orr, progression -free survival – PFS, general survival – OS and biomarker data, including CD33+ MDSC and T cell activity. Initial proof data are expected at the end of 2025.

Actimab-a, the main radiotherapeutic of the actin, offers Actinium-225, a powerful alpha-emeanor radioisot designed to induce lethal DNA damage. It was studied in over 150 patients with acute myeloid leukemia – AML and advances to a recording/refractory registration study in 2025.

The management of the actin considers this program as a potential discovery for patients whose cancer progresses despite treatment with PD-1 inhibitors. The company estimates that over 500,000 patients could benefit from this approach, strengthening the potential as a targeted radiotherapy.

ATNM currently trades $ 1,225 or 5,7692% lower on NYSE.